We also validated NEK2 as a novel therapeutic target in the TP53−/− subset of MM and revealed a novel mechanism by which TP53 regulates NEK2 at both the genetic and transcriptional levels. The gene discussed is NEK2; the disease is Miyoshi myopathy.